These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24134602)

  • 1. Insulin degludec: a new insulin for today?
    Hitman GA
    Diabet Med; 2013 Nov; 30(11):1267. PubMed ID: 24134602
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Hitman. Insulin degludec: a new insulin for today?
    Schmidt TA
    Diabet Med; 2014 Mar; 31(3):377-8. PubMed ID: 24354502
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrated insulins in current clinical practice.
    Schloot NC; Hood RC; Corrigan SM; Panek RL; Heise T
    Diabetes Res Clin Pract; 2019 Feb; 148():93-101. PubMed ID: 30583034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insulins and New Aspects in Insulin Delivery.
    Woo VC
    Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
    Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
    Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not all long-acting insulins are the same.
    Harmel AL; Somma L
    Diabetes Care; 2002 Sep; 25(9):1666-7. PubMed ID: 12196454
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin degludec (Tresiba)--a new long-acting insulin for diabetes.
    Med Lett Drugs Ther; 2015 Dec; 57(1483):163-4. PubMed ID: 26633683
    [No Abstract]   [Full Text] [Related]  

  • 10. Integrating advances in insulin into clinical practice: Overview of current insulin formulations.
    Rhinehart AS
    J Fam Pract; 2013 Sep; 62(9 Suppl Insulin):S4-8. PubMed ID: 24080572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glargine and cancer: can we now suggest closure?
    Owens DR
    Diabetes Care; 2012 Dec; 35(12):2426-8. PubMed ID: 23173130
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec: a new ultra-longacting insulin.
    Tahrani AA; Bailey CJ; Barnett AH
    Lancet; 2012 Apr; 379(9825):1465-7. PubMed ID: 22521058
    [No Abstract]   [Full Text] [Related]  

  • 14. Premix insulins in type 1 diabetes: the coming of degludec/aspart.
    Rendell M
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):341-348. PubMed ID: 30789066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
    Weatherall J; Bloudek L; Buchs S
    Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.
    Rendell M
    Drug Des Devel Ther; 2017; 11():1209-1220. PubMed ID: 28458515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulins for type 2 diabetes.
    Med Lett Drugs Ther; 2019 May; 61(1571):65-68. PubMed ID: 31169803
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.